Biofrontera News - B8F

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px;...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px;...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px;...

AIM 18 February 2016 NOTICE 18/02/2016 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM BIOFRONTERA AG At the request of the company...

Leverkusen, Germany, Feb. 16, 2016 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px;...

News) - Biofrontera AG said Tuesday that it has raised EUR4.4 million in a placing of 4.48 billion shares at EUR1.90, ...

Biofrontera AG 16 February 2016 Biofrontera AG ("Biofrontera" or the "Company") Private Placement Leverkusen, Germany...

News) - Biofrontera AG said Thursday its phase III trials for its drug candidate BF-200 ALA showed very high efficacy, ...

LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px;...

Biofrontera AG 11 February 2016 Data from pivotal Phase III studies with BF-200 ALA: First introduction to US dermatologists as a poster and two...

News) - Biofrontera AG Thursday said it had seen "excellent" results from a phase III study of its Ameluz treatment fo ...